| European Case Law Identifier: | ECLI:EP:BA:2013:T186911.20130322 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 22 March 2013 | ||||||||
| Case number: | T 1869/11 | ||||||||
| Application number: | 03704789.1 | ||||||||
| IPC class: | A61K 9/12 A61K 31/726 A61K 31/727 A61P 11/00 A61K 9/72 A61K 31/728 |
||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | D | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | Use of glycosaminoglycans such as E.G. heparin for the treatment of respiratory disorders such as COPD | ||||||||
| Applicant name: | Ockham Biotech Limited | ||||||||
| Opponent name: | Vectura Limited | ||||||||
| Board: | 3.3.02 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | New main request - admission (yes) Added matter (no) Sufficiency of disclosure, novelty and inventive step (yes) Remittal (no) |
||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t111869eu1.html
Date retrieved: 17 May 2021
13 references found.
Click X to load a reference inside the current page, click on the title to open in a new page.EPC Articles
Case Law Book: I Patentability
Case Law Book: II Conditions to be met by an Application
XCLR II E 1.6.1 Combination of features pertaining to separate embodiments; application as filed is not a "reservoir"